Bexxar may be a antibody that’s joined with hot iodine I-131. Organism antibodies area unit created to focus onand destroy solely bound cells within the body. This might facilitate to guard healthy cells from injury.
Bexxar is employed to treat bound types of non-Hodgkin’s cancer. it’s typically given when alternative medicationsare tried while not productive treatment.

Bexxar may be used for functions ex-directory during this medication guide.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Bexxar Dosimetric, BexxarTherapeutic
  • Serious and sometimes fatal allergic reactions may occur during treatment with Bexxar. Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, or have a fever, chills, chest tightness, wheezing, or trouble breathing. These effects can occur during the injection or up to 48 hours later.

    Get emergency medical help if you have any signs of an allergic reaction to Bexxar: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

    Call your doctor at once if you have:

    pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
    easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
    weakness, tired feeling, fever, chills, sore throat, body aches, flu symptoms;
    blood in your urine or stools, coughing up blood or vomit that looks like coffee grounds; or
    stabbing chest pain, wheezing, cough with yellow or green mucus; feeling short of breath.
    Common Bexxarside effects may include:

    nausea, vomiting, diarrhea, stomach pain, loss of appetite;
    joint or muscle pain;
    headache; or
    mild itching or rash.
  • Dosimetric dose : Bexxar 450 mg IV infusion over 60 minutes followed by I-131 tositumomab 5 mCi I-131 and 35 mg protein IV infusion over 20 minutes Therapeutic dose: Bexxar 450 mg IV infusion over 60 minutes followed by I-131 tositumomab dose calculated to deliver 75 cGy total body irradiation for patients with normal platelet count (platelet count greater than 150,000/mm3 obtained within 28 days prior to dosing) 7 to 14 days after dosimetric step Comments: -Do not administer the therapeutic dose if biodistribution is altered. -See manufacturer's product information for instructions on assessing dosimetry and biodistribution and calculating the therapeutic dose.